The European Commission grants final approval for elranatamab for the treatment of relapsed or refractory myeloma
The European Commission has granted conditional marketing authorisation for elranatamab, also known as Elrexfio® marketed by the pharmaceutical company Pfizer. This follows an earlier positive recommendation from the European Medicines Agency (EMA – the EU…